ISCT in the News

 2025    2024   2023

Scientific societies call for a moratorium on using CRISPR to create genetically modified children
May 13, 2025

ISCT, ASGCT, and ARM in process of publishing a joint position to offer guidance and to recommend a 10-year moratorium to countries deciding whether and/or how to regulate germline and other genome editing. 

Advocacy groups and experts call for decade-long ban on germline editing

May 13, 2025

Cell and gene therapy advocacy organizations are jointly calling for a 10-year international moratorium on gene editing of the human germline.

Preparing for the Future: What will ISCT 2025 Deliver? 

Apr 30, 2025

Phil Vanek, PhD, ISCT Chief Commercialization Officer, sits down with the RegMedNet team to discuss upcoming highlights from ISCT 2025 New Orleans

Advancing innovation and impact at ISCT 2025

Apr 25, 2025

Miguel Forte, MD, PhD, ISCT President, shares his insights on what sets ISCT 2025 apart from other sector events 

ISCT Announces Dr. Phil Vanek as next Chief Commercialization Officer

Jan 30, 2025

The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Phil Vanek, PhD, as ISCT Chief Commercialization Officer (CCO), effective January 1, 2025, through December 31, 2026.